← boardnext 2027-06next 2027-12
ALXO
ALX Oncology Inc.distress 5/10 · elevated risk$1.95-3%today-25% from 52w high
Oncology 3
Lead: Head and Neck Cancer · target PD-1
Revenue
pre-revenue
Liquidity
$169M
Runway
2.2 yrs
Shares 1y
+151%
Price & events
+32.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.5%
1D
-5.8%
1W
+10.8%
1M
+22.6%
3M
+39.3%
6M
+285.4%
1Y
-70.7%
2Y
-96.7%
5Y
-97.6%
All
Overview
- Market Cap
- $262.40M
- Enterprise Value
- $233.41M
- Volume
- 46.85K
- 52 Week Range
- $0.47 – $2.60
- Total Shares
- 134.56M
- Float Shares
- 77.44M
- Short %
- 5.22%
- % Held by Insiders
- 0.92%
- % Held by Institutions
- 78.79%
- RVOL
- 0.03x
- Beta
- 0.43
Pipeline stages · 2 programs
ALX2004
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Evorpacept (ALX148), Trastuzumab, Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-01 | Phase 1 | ALX2004 | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC) | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | Evorpacept (ALX148), Trastuzumab, Paclitaxel | Breast Cancer, Metastatic | — | recruiting |
| 2025-06-27 | Phase 1 | Evorpacept, Enfortumab Vedotin | Bladder Cancer, Urothelial Carcinoma | 36 | completed |
| 2025-03-03 | Phase 2 | evorpacept, pembrolizumab | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | 189 | active not recruiting |
| 2025-03-03 | Phase 2 | evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | 172 | active not recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-01-17 | Phase 1 | evorpacept, azacitidine | Higher Risk Myelodysplastic Syndromes | 65 | terminated |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 4
- Q3 2026Guided 70%readoutPhase 2evorpacept · Anticipated interim data readout for ASPEN-Breast trialSEC 8-K
- 2026-08-11earningsEarningsEarnings releaseyahoo
- Q4 2025conferencedata presentationsecondaryevorpacept · Updated ASPEN-06 trial data presentationSEC 8-K
- August 2025trial initiationsecondaryPhase 1ALX2004 · First patient enrollmentSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-19Wells FargoOverweight
- 2026-03-10HC Wainwright & Co.Buy
- 2026-02-05Piper SandlerOverweight
- 2025-05-21UBSBuy
- 2025-05-09HC Wainwright & Co.Buy
- 2025-03-07StifelHold
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- TNGXTango Therapeutics, Inc.$4.0B · D5
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-21ALX Oncology (ALXO) Status Update Summary - Quartr
- 2026-07-08ALXO Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - Estimate Uncertainty - dars.gov.et
- 2026-07-08ALX Oncology (ALXO) Jefferies London Healthcare Conference 2025 Summary - Quartr
- 2026-07-06ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations - Stock Titan
- 2026-07-05ALXO - Alx Oncology Holdings Inc Options - Finviz
- 2026-07-02ALX Oncology (ALXO) Edges Higher as Biotech Sector Shows Selective Interest - Last Point Support - DonanımHaber
- 2026-06-30ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
- 2026-06-30ALX Oncology's Corey Goodman resigns as Chairman and director - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.